Week's news analysis

CordenPharma Inaugurates Increased Peptide Production

By Editors - 11 September 2023
[Photo by CordenPharma] CordenPharma CEO Dr. Michael Quirmbach and CordenPharma Colorado Managing Director Brian McCudden at a ribbon cutting on 22 August 2023 to inaugurate increased peptide production in CordenPharma Colorado's newly-updated large-scale manufacturing facility with expanded SPPS processing and solvent logistics capabilities, including a modernized tank farm (on left) and filter dryer for crude peptide isolation (on right).

Following the signing of a multi-year, large-scale peptide manufacturing agreement earlier this year, CordenPharma announced the inauguration of increased commercial peptide production capacity with newly-upgraded facilities at CordenPharma Colorado, the largest Solid-Phase Peptide Synthesis (SPPS) Manufacturing facility worldwide.

After kicking off capital investments in early 2023, CordenPharma successfully completed a series of upgrades and modernizations to the facility which have increased the efficiency and throughput of SPPS peptide production, allowing for increased capacity to service current and future customers across a growing pharmaceutical innovator base.

The extensive Capital Expenditure initiative includes: Upgrades to their existing 10'000 L reactor volume with a batch size exceeding 400 kg (> 35 Amino Acids), and a yearly capacity of > 2 Metric Tons of Peptide; A 50% increase in downstream HPLC purification capacity.

With decades of proven SPPS production, CordenPharma Colorado is pleased to expand their team of experts to accommodate the overall capacity increase and resulting project demand. On top of its existing workforce of > 500 employees, they expect to add another 60 employees, with additional staff in the future as needed.

As a continuation of CordenPharma's 2023 investment strategy across all technology platforms including peptides, the updates of the world's largest SPPS peptide capacity perfectly complements CordenPharma's robust end-to-end service offerings with fully-integrated sterile injectable capabilities in CordenPharma Caponago (IT), including recently-expanded LNP Formulation and Fill & Finish capacity.

Dr. Stéphane Varray, CordenPharma's Global Peptide Platform Director, added: "CordenPharma is pleased to celebrate the start of peptide production in our newly-upgraded and expanded SPPS manufacturing facility in Colorado with the largest worldwide peptide capacity available. These modernizations will allow for increased efficiency, throughput, and access to state-of-the-art technologies for streamlined commercial peptide API supply. Our team at CordenPharma Colorado brings unparalleled expertise in proven peptide production across all scales and phases, which is fully-integrated with our flexible sterile injectable capabilities. We look forward to supporting an expanding base of pharmaceutical innovators with bespoke peptide supply tailored to support the complex modalities of their therapeutic drug development and commercialization journey."

TO READ CordenPharma announces entry into Oligonucleotide manufacturing

Go to Top